• 1
    Kawakami, Y. and Rosenberg, S. A., Human tumor antigens recognized by T-cells. Immunol. Res. 1997. 16: 313339.
  • 2
    Scanlan, M. J., Gure, A. O., Jungbluth, A. A., Old, L. J. and Chen, Y. -T., Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol. Rev. 2002. 188: 2232.
  • 3
    Boon, T., Coulie, P. G., Van den Eynde, B. J. and van der Bruggen, P., Human T cell responses against melanoma. Annu. Rev. Immunol. 2006. 24: 175208.
  • 4
    Shevach, E. M., CD4+ CD25+ suppressor T cells: more questions than answers. Nat. Rev. Immunol. 2002. 2: 389400.
  • 5
    Sakaguchi, S., Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 2004. 22: 531562.
  • 6
    Nishikawa, H. and Sakaguchi, S., Regulatory T cells in tumor immunity. Int. J. Cancer 2010. 127: 759767.
  • 7
    Sakaguchi, S., Miyara, M., Costantino, C. M. and Hafler, D. A., FOXP3+ regulatory T cells in the human immune system. Nat. Rev. Immunol. 2010. 10: 490500.
  • 8
    Onizuka, S., Tawara, I., Shimizu, J., Sakaguchi, S., Fujita, T. and Nakayama, E., Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody. Cancer Res. 1999. 59: 31283133.
  • 9
    Shimizu, J., Yamazaki, S. and Sakaguchi, S., Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 1999. 163: 52115218.
  • 10
    Nishikawa, H., Kato, T., Tanida, K., Hiasa, A., Tawara, I., Ikeda, H., Ikarashi, Y. et al., CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses. Proc. Natl. Acad. Sci. USA. 2003. 100: 1090210906.
  • 11
    Nishikawa, H., Kato, T., Tawara, I., Saito, K., Ikeda, H., Kuribayashi, K., Allen, P. M. et al., Definition of target antigens for naturally occurring CD4+ CD25+ regulatory T cells. J. Exp. Med. 2005. 201: 681686.
  • 12
    Nishikawa, H., Kato, T., Tawara, I., Takemitsu, T., Saito, K., Wang, L., Ikarashi, Y. et al., Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts. Proc. Natl. Acad. Sci. USA. 2005. 102: 92539257.
  • 13
    Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M. et al., Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004. 10: 942949.
  • 14
    Sato, E., Olson, S. H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., Jungbluth, A. A. et al., Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. USA. 2005. 102: 1853818543.
  • 15
    Dannull, J., Su, Z., Rizzieri, D., Yang, B. K., Coleman, D., Yancey, D., Zhang, A. et al., Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 2005. 115: 36233633.
  • 16
    Chen, Y.-T., Scanlan, M. J., Sahin, U., Tureci, O., Gure, A. O., Tsang, S., Williamson, B. et al., A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. U S A. 1997. 94: 19141918.
  • 17
    Gnjatic, S., Nishikawa, H., Jungbluth, A. A., Gure, A. O., Ritter, G., Jager, E., Knuth, A. et al., NY-ESO-1: review of an immunogenic tumor antigen. Adv. Cancer Res. 2006. 95: 130.
  • 18
    Gnjatic, S., Nagata, Y., Jager, E., Stockert, E., Shankara, S., Roberts, B. L., Mazzara, G. P. et al., Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. Proc. Natl. Acad. Sci. U S A. 2000. 97: 1091710922.
  • 19
    Danke, N. A., Koelle, D. M., Yee, C., Beheray, S. and Kwok, W. W., Autoreactive T cells in healthy individuals. J. Immunol. 2004. 172: 59675972.
  • 20
    Nishikawa, H., Jager, E., Ritter, G., Old, L. J. and Gnjatic, S., CD4+CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients. Blood 2005. 106: 10081011.
  • 21
    Nishikawa, H., Qian, F., Tsuji, T., Ritter, G., Old, L. J., Gnjatic, S. and Odunsi, K., Influence of CD4+CD25+ regulatory T cells on low/high-avidity CD4+ T cells following peptide vaccination. J. Immunol. 2006. 176: 63406346.
  • 22
    Iwasaki, A. and Medzhitov, R., Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 2004. 5: 987995.
  • 23
    Pasare, C. and Medzhitov, R., Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003. 299: 10331036.
  • 24
    Sutmuller, R. P., den Brok, M. H., Kramer, M., Bennink, E. J., Toonen, L. W., Kullberg, B. J., Joosten, L. A. et al., Toll-like receptor 2 controls expansion and function of regulatory T cells. J. Clin. Invest. 2006. 116: 485494.
  • 25
    Liu, H. Y., Komai-Koma, M., Xu, D. and Liew, F. Y., Toll-like receptor 2 signaling modulates the functions of CD4+CD25+ regulatory T cells. Proc. Natl. Acad. Sci. USA. 2006. 103: 70487053.
  • 26
    Yang, Y., Huang, C. T., Huang, X. and Pardoll, D. M., Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat. Immunol. 2004. 5: 508515.
  • 27
    Nishikawa, H., Sato, E., Briones, G., Chen, L. M., Matsuo, M., Nagata, Y., Ritter, G. et al., In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines. J. Clin. Invest. 2006. 116: 19461954.
  • 28
    Nishikawa, H., Tsuji, T., Jager, E., Briones, G., Ritter, G., Old, L. J., Galan, J. E. et al., Induction of regulatory T cell-resistant helper CD4+ T cells by bacterial vector. Blood 2008. 111: 14041412.
  • 29
    Nakahara, S., Tsunoda, T., Baba, T., Asabe, S. and Tahara, H., Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide. Cancer Res. 2003. 63: 41124118.
  • 30
    Okamoto, M., Oshikawa, T., Tano, T., Ohe, G., Furuichi, S., Nishikawa, H., Ahmed, S. U. et al., Involvement of toll-like receptor 4 signaling in interferon-γ production and antitumor effect by streptococcal agent OK-432. J. Natl. Cancer Inst. 2003. 95: 316326.
  • 31
    Okamoto, M., Oshikawa, T., Tano, T., Ahmed, S. U., Kan, S., Sasai, A., Akashi, S. et al., Mechanism of anticancer host response induced by OK-432, a streptococcal preparation, mediated by phagocytosis and Toll-like receptor 4 signaling. J. Immunother. 2006. 29: 7886.
  • 32
    Ono, T., Harada, M., Yamada, A., Tanaka, M., Takao, Y., Tanaka, Y., Mine, T. et al., Antitumor effects of systemic and local immunization with a CTL-directed peptide in combination with a local injection of OK-432. Clin. Cancer Res. 2006. 12: 13251332.
  • 33
    Oshikawa, T., Okamoto, M., Tano, T., Sasai, A., Kan, S., Moriya, Y., Ryoma, Y. et al., Antitumor effect of OK-432-derived DNA: one of the active constituents of OK-432, a streptococcal immunotheropeutic agent. J. Immunother. 2006. 29: 143150.
  • 34
    Okamoto, M., Furuichi, S., Nishioka, Y., Oshikawa, T., Tano, T., Ahmed, S. U., Takeda, K. et al., Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation. Cancer Res. 2004. 64: 54615470.
  • 35
    Rosenberg, S. A., Yang, J. C. and Restifo, N. P., Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 2004. 10: 909915.
  • 36
    Dougan, M. and Dranoff, G., Immune therapy for cancer. Annu. Rev. Immunol. 2009. 27: 83117.
  • 37
    Napolitani, G., Rinaldi, A., Bertoni, F., Sallusto, F. and Lanzavecchia, A., Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. 2005. 6: 769776.
  • 38
    Warger, T., Osterloh, P., Rechtsteiner, G., Fassbender, M., Heib, V., Schmid, B., Schmitt, E. et al., Synergistic activation of dendritic cells by combined toll-like receptor ligation induces superior CTL responses in vivo. Blood 2006. 108: 544550.
  • 39
    King, I. L. and Segal, B. M., Cutting edge: IL-12 induces CD4+CD25- T cell activation in the presence of T regulatory cells. J. Immunol. 2005. 175: 641645.
  • 40
    Zhao, J. X., Zhao, J. C. and Perlman, S., Differential effects of IL-12 on Tregs and non-Treg T cells: roles of IFN-γ, IL-2 and IL-2R. Plos One 2012. 7: e46241.
  • 41
    Setoguchi, R., Hori, S., Takahashi, T. and Sakaguchi, S., Homeostatic maintenance of natural Foxp3+ CD25+ CD4+ regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J. Exp. Med. 2005. 201: 723735.
  • 42
    Oldenhove, G., Bouladoux, N., Wohlfert, E. A., Hall, J. A., Chou, D., Dos Santos, L., O'Brien, S. et al., Decrease of Foxp3+ Treg cell number and acquisition of effector cell phenotype during lethal infection. Immunity 2009. 31: 772786.
  • 43
    Wan, Y. S. Y. and Flavell, R. A., Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. Nature 2007. 445: 766770.
  • 44
    Gnjatic, S., Altorki, N. K., Tang, D. N., Tu, S. M., Kundra, V., Ritter, G., Old, L. J. et al., NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells. Clin. Cancer Res. 2009. 15: 21302139.
  • 45
    Zhou, G., Drake, C. G. and Levitsky, H. I., Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood 2006. 107: 628636.
  • 46
    Bonertz, A., Weitz, J., Pietsch, D. H. K., Rahbari, N. N., Schlude, C., Ge, Y. Z., Juenger, S. et al., Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J. Clin. Invest. 2009. 119: 33113321.
  • 47
    Aoki, M., Ueda, S., Nishikawa, H., Kitano, S., Hirayama, M., Ikeda, H., Toyoda, H. et al., Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432. Vaccine 2009. 27: 68546861.
  • 48
    Gnjatic, S., Atanackovic, D., Jager, E., Matsuo, M., Selvakumar, A., Altorki, N. K., Maki, R. G. et al., Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc. Natl. Acad. Sci. U S A. 2003. 100: 88628867.
  • 49
    Stockert, E., Jager, E., Chen, Y.-T., Scanlan, M. J., Gout, I., Karbach, J., Arand, M. et al., A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J. Exp. Med. 1998. 187: 13491354.
  • 50
    Riddell, S. R. and Greenberg, P. D., The use of anti-CD3 and anti-CD28 monoclonal-antibodies to clone and expand human antigen-specific T-cells. J. Immunol. Methods 1990. 128: 189201.
  • 51
    Nagata, Y., Ono, S., Matsuo, M., Gnjatic, S., Valmori, D., Ritter, G., Garrett, W. et al., Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations. Proc. Natl. Acad. Sci. U S A. 2002. 99: 1062910634.